View in EDS

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.

Saved in:
Bibliographic Details
Title: Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Authors: Corcoran RB; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Do KT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kim JE; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Parikh AR; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Yeku OO; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Xiong N; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Weekes CD; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Veneris J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Ahronian LG; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Mauri G; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, and Department of Hematology Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Tian J; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Norden BL; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Michel AG; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Van Seventer EE; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Siravegna G; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Camphausen K; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Chi G; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Fetter IJ; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Brugge JS; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts., Chen H; National Institute of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Bethesda, Maryland., Takebe N; National Institute of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Bethesda, Maryland., Penson RT; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Juric D; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Flaherty KT; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Sullivan RJ; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Clark JW; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Heist RS; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts., Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 01; Vol. 30 (9), pp. 1739-1749.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38456660
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Corcoran+RB%22">Corcoran RB</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Do+KT%22">Do KT</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Kim+JE%22">Kim JE</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Cleary+JM%22">Cleary JM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Parikh+AR%22">Parikh AR</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Yeku+OO%22">Yeku OO</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Xiong+N%22">Xiong N</searchLink>; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Weekes+CD%22">Weekes CD</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Veneris+J%22">Veneris J</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Ahronian+LG%22">Ahronian LG</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Mauri+G%22">Mauri G</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, and Department of Hematology Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Tian+J%22">Tian J</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Norden+BL%22">Norden BL</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Michel+AG%22">Michel AG</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Van+Seventer+EE%22">Van Seventer EE</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Siravegna+G%22">Siravegna G</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Camphausen+K%22">Camphausen K</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Chi+G%22">Chi G</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Fetter+IJ%22">Fetter IJ</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Brugge+JS%22">Brugge JS</searchLink>; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Chen+H%22">Chen H</searchLink>; National Institute of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Takebe+N%22">Takebe N</searchLink>; National Institute of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Bethesda, Maryland.<br /><searchLink fieldCode="AU" term="%22Penson+RT%22">Penson RT</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Juric+D%22">Juric D</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Flaherty+KT%22">Flaherty KT</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Sullivan+RJ%22">Sullivan RJ</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Clark+JW%22">Clark JW</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Heist+RS%22">Heist RS</searchLink>; Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Matulonis+UA%22">Matulonis UA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Liu+JF%22">Liu JF</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Shapiro+GI%22">Shapiro GI</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2024 May 01; Vol. 30 (9), pp. 1739-1749.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38456660
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-23-3135
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1739
    Titles:
      – TitleFull: Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Corcoran RB
      – PersonEntity:
          Name:
            NameFull: Do KT
      – PersonEntity:
          Name:
            NameFull: Kim JE
      – PersonEntity:
          Name:
            NameFull: Cleary JM
      – PersonEntity:
          Name:
            NameFull: Parikh AR
      – PersonEntity:
          Name:
            NameFull: Yeku OO
      – PersonEntity:
          Name:
            NameFull: Xiong N
      – PersonEntity:
          Name:
            NameFull: Weekes CD
      – PersonEntity:
          Name:
            NameFull: Veneris J
      – PersonEntity:
          Name:
            NameFull: Ahronian LG
      – PersonEntity:
          Name:
            NameFull: Mauri G
      – PersonEntity:
          Name:
            NameFull: Tian J
      – PersonEntity:
          Name:
            NameFull: Norden BL
      – PersonEntity:
          Name:
            NameFull: Michel AG
      – PersonEntity:
          Name:
            NameFull: Van Seventer EE
      – PersonEntity:
          Name:
            NameFull: Siravegna G
      – PersonEntity:
          Name:
            NameFull: Camphausen K
      – PersonEntity:
          Name:
            NameFull: Chi G
      – PersonEntity:
          Name:
            NameFull: Fetter IJ
      – PersonEntity:
          Name:
            NameFull: Brugge JS
      – PersonEntity:
          Name:
            NameFull: Chen H
      – PersonEntity:
          Name:
            NameFull: Takebe N
      – PersonEntity:
          Name:
            NameFull: Penson RT
      – PersonEntity:
          Name:
            NameFull: Juric D
      – PersonEntity:
          Name:
            NameFull: Flaherty KT
      – PersonEntity:
          Name:
            NameFull: Sullivan RJ
      – PersonEntity:
          Name:
            NameFull: Clark JW
      – PersonEntity:
          Name:
            NameFull: Heist RS
      – PersonEntity:
          Name:
            NameFull: Matulonis UA
      – PersonEntity:
          Name:
            NameFull: Liu JF
      – PersonEntity:
          Name:
            NameFull: Shapiro GI
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2024 May 01
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1